Citius Pharmaceuticals sales and marketing update

Citius said it will discontinue FDA-approved Suprenza phentermine orally disintegrating tablets to treat obesity. The company noted the obesity and weight management market has “shifted” and the sympathomimetic amine anorectic “no longer meets our core strategic objectives.” The company will focus on developing Mino-Lok and Hydro-Lido. Mino-Lok, an antibiotic lock solution, is in Phase III testing to treat catheter-related bloodstream infections. Hydro-Lido, a topical cream composed of hydrocortisone and lidocaine, is in Phase IIb testing to treat hemorrhoids. ...